Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1917 2
1918 2
1954 1
1961 8
1962 7
1963 5
1964 10
1965 7
1966 10
1967 14
1968 10
1969 11
1970 11
1971 14
1972 4
1973 9
1974 12
1975 20
1976 16
1977 19
1978 14
1979 12
1980 15
1981 21
1982 23
1983 33
1984 20
1985 22
1986 39
1987 43
1988 52
1989 55
1990 48
1991 44
1992 40
1993 55
1994 43
1995 54
1996 60
1997 62
1998 61
1999 68
2000 62
2001 63
2002 75
2003 71
2004 105
2005 77
2006 90
2007 83
2008 80
2009 110
2010 115
2011 121
2012 116
2013 87
2014 111
2015 125
2016 136
2017 143
2018 157
2019 142
2020 192
2021 216
2022 172
2023 171
2024 205
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,741 results

Results by year

Filters applied: . Clear all
Page 1
Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.
Drilon A, Camidge DR, Lin JJ, Kim SW, Solomon BJ, Dziadziuszko R, Besse B, Goto K, de Langen AJ, Wolf J, Lee KH, Popat S, Springfeld C, Nagasaka M, Felip E, Yang N, Velcheti V, Lu S, Kao S, Dooms C, Krebs MG, Yao W, Beg MS, Hu X, Moro-Sibilot D, Cheema P, Stopatschinskaja S, Mehta M, Trone D, Graber A, Sims G, Yuan Y, Cho BC; TRIDENT-1 Investigators. Drilon A, et al. Among authors: goto k. N Engl J Med. 2024 Jan 11;390(2):118-131. doi: 10.1056/NEJMoa2302299. N Engl J Med. 2024. PMID: 38197815 Clinical Trial.
First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC.
Zhou C, Solomon B, Loong HH, Park K, Pérol M, Arriola E, Novello S, Han B, Zhou J, Ardizzoni A, Mak MP, Santini FC, Elamin YY, Drilon A, Wolf J, Payakachat N, Uh MK, Rajakumar D, Han H, Puri T, Soldatenkova V, Lin AB, Lin BK, Goto K; LIBRETTO-431 Trial Investigators. Zhou C, et al. Among authors: goto k. N Engl J Med. 2023 Nov 16;389(20):1839-1850. doi: 10.1056/NEJMoa2309457. Epub 2023 Oct 21. N Engl J Med. 2023. PMID: 37870973 Free PMC article. Clinical Trial.
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
Drilon A, Siena S, Dziadziuszko R, Barlesi F, Krebs MG, Shaw AT, de Braud F, Rolfo C, Ahn MJ, Wolf J, Seto T, Cho BC, Patel MR, Chiu CH, John T, Goto K, Karapetis CS, Arkenau HT, Kim SW, Ohe Y, Li YC, Chae YK, Chung CH, Otterson GA, Murakami H, Lin CC, Tan DSW, Prenen H, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Doebele RC; trial investigators. Drilon A, et al. Among authors: goto k. Lancet Oncol. 2020 Feb;21(2):261-270. doi: 10.1016/S1470-2045(19)30690-4. Epub 2019 Dec 11. Lancet Oncol. 2020. PMID: 31838015 Free PMC article.
Endothelin XIII.
Emoto N, Masaki T, Goto K, Vanhoutte PM, Yanagisawa M. Emoto N, et al. Among authors: goto k. Life Sci. 2014 Nov 24;118(2):47-50. doi: 10.1016/j.lfs.2014.09.021. Epub 2014 Sep 28. Life Sci. 2014. PMID: 25264369 Free article.
[Pneumonectomy and lobectomy].
Goto K. Goto K. Masui. 2014 May;63(5):513-21. Masui. 2014. PMID: 24864572 Review. Japanese.
Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer.
Kenmotsu H, Yamamoto N, Yamanaka T, Yoshiya K, Takahashi T, Ueno T, Goto K, Daga H, Ikeda N, Sugio K, Seto T, Toyooka S, Date H, Mitsudomi T, Okamoto I, Yokoi K, Saka H, Okamoto H, Takiguchi Y, Tsuboi M. Kenmotsu H, et al. Among authors: goto k. J Clin Oncol. 2020 Jul 1;38(19):2187-2196. doi: 10.1200/JCO.19.02674. Epub 2020 May 14. J Clin Oncol. 2020. PMID: 32407216 Clinical Trial.
TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer.
Oxnard GR, Yang JC, Yu H, Kim SW, Saka H, Horn L, Goto K, Ohe Y, Mann H, Thress KS, Frigault MM, Vishwanathan K, Ghiorghiu D, Ramalingam SS, Ahn MJ. Oxnard GR, et al. Among authors: goto k. Ann Oncol. 2020 Apr;31(4):507-516. doi: 10.1016/j.annonc.2020.01.013. Epub 2020 Jan 24. Ann Oncol. 2020. PMID: 32139298 Free article. Clinical Trial.
Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer.
Cho BC, Chiu CH, Massarelli E, Buchschacher GL, Goto K, Overbeck TR, Loong HHF, Chee CE, Garrido P, Dong X, Fan Y, Lu S, Schwemmers S, Bordogna W, Zeuner H, Osborne S, John T. Cho BC, et al. Among authors: goto k. Lung Cancer. 2024 Feb;188:107442. doi: 10.1016/j.lungcan.2023.107442. Epub 2023 Dec 15. Lung Cancer. 2024. PMID: 38171156 Free article.
Rain Leaks Under the Trusted Tree.
Goto K. Goto K. J Thorac Oncol. 2024 Jul;19(7):963-965. doi: 10.1016/j.jtho.2024.04.016. J Thorac Oncol. 2024. PMID: 38972708 No abstract available.
3,741 results